Bell Investment Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Bell Investment Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.65K	Hold	307	–	–	﹤0.01%	719
2026 Q1	$7.6K	Buy	307 +197	+179%	+$4.69K	﹤0.01%	793
2025 Q4	$2.57K	Sell	110 -24	-18%	-$535	﹤0.01%	1259
2025 Q3	$2.64K	Sell	134 -67	-33%	-$1.38K	﹤0.01%	1217
2025 Q2	$4.36K	Buy	201 +43	+27%	+$1.01K	﹤0.01%	1045
2025 Q1	$3.83K	Buy	158 +23	+17%	+$518	﹤0.01%	1033
2024 Q4	$2.82K	Buy	135 +17	+14%	+$365	﹤0.01%	1196
2024 Q3	$2.35K	Hold	118	–	–	﹤0.01%	1283
2024 Q2	$1.83K	Hold	118	–	–	﹤0.01%	1387
2024 Q1	$1.88K	Sell	118 -43	-27%	-$648	﹤0.01%	1386
2023 Q4	$2.71K	Sell	161 -36	-18%	-$492	﹤0.01%	1199
2023 Q3	$2.3K	Buy	+197	New	+$2.63K	﹤0.01%	1196
2023 Q2	–	Sell	-39	Closed	-$647	–	1936
2023 Q1	$647	Hold	39	–	–	﹤0.01%	1704
2022 Q4	$725	Hold	39	–	–	﹤0.01%	1670
2022 Q3	$1K	Buy	+39	New	+$462	﹤0.01%	1361

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bell Investment Advisors's CPRX Position: Q2 2026 in Review

Bell Investment Advisors held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 307 shares worth $9.65K. The position accounts for ﹤0.01% of the portfolio, ranked #719.

Bell Investment Advisors first reported a position in CPRX in Q3 2022 and has held it in 15 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Bell Investment Advisors held 307 shares of Catalyst Pharmaceutical worth $9.65K as of Q2 2026.
Bell Investment Advisors left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
Catalyst Pharmaceutical made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #719 holding.
Bell Investment Advisors first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 15 quarters since.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.